Meet our SPARK Fellows
Introducing Cohort 7
Cohort 6
Michael Wempe, PhD
A Novel Therapeutic Approach to Genitourinary Syndrome of Menopause
Email Address:MICHAEL.WEMPE@CUANSCHUTZ.EDU
A Novel Therapeutic Approach to Genitourinary Syndrome of Menopause
This project aims to address the genitourinary syndrome of menopause (GSM) in postmenopausal women, which includes symptoms like painful intercourse, incontinence, and increased vaginal and urinary tract infections. The proposed solution is a small molecule drug to be delivered locally via cream, tablet suppository, or vaginal ring that activates estrogen receptors to regenerate tissue locally. Unlike traditional estrogen-based therapies, this drug is designed to be rapidly inactivated, ensuring that it won't impose any systemic action. The team has conducted promising proof-of-principle studies in ovariectomized rats and plans to synthesize additional compounds, develop improved formulation strategies, and conduct efficacy and toxicity studies to determine appropriate dosing. If successful, this drug could benefit millions of postmenopausal women, including breast cancer survivors for whom estrogen-based therapies are contraindicated. The team brings together expertise in chemical synthesis, formulation, pharmacokinetics, and drug development, making them well-suited for this project. Collaborators: Steven Nordeen, PhD, David Orlicky, PhD and Thomas Anchordoquy, PhD
Learn more about Dr. WempeCohort 5
Michael Wempe, PhD
A Novel Therapeutic Approach to Genitourinary Syndrome of Menopause
Email Address:MICHAEL.WEMPE@CUANSCHUTZ.EDU
A Novel Therapeutic Approach to Genitourinary Syndrome of Menopause
This project aims to address the genitourinary syndrome of menopause (GSM) in postmenopausal women, which includes symptoms like painful intercourse, incontinence, and increased vaginal and urinary tract infections. The proposed solution is a small molecule drug to be delivered locally via cream, tablet suppository, or vaginal ring that activates estrogen receptors to regenerate tissue locally. Unlike traditional estrogen-based therapies, this drug is designed to be rapidly inactivated, ensuring that it won't impose any systemic action. The team has conducted promising proof-of-principle studies in ovariectomized rats and plans to synthesize additional compounds, develop improved formulation strategies, and conduct efficacy and toxicity studies to determine appropriate dosing. If successful, this drug could benefit millions of postmenopausal women, including breast cancer survivors for whom estrogen-based therapies are contraindicated. The team brings together expertise in chemical synthesis, formulation, pharmacokinetics, and drug development, making them well-suited for this project. Collaborators: Steven Nordeen, PhD, David Orlicky, PhD and Thomas Anchordoquy, PhD
Learn more about Dr. WempeCohort 4
Michael Wempe, PhD
A Novel Therapeutic Approach to Genitourinary Syndrome of Menopause
Email Address:MICHAEL.WEMPE@CUANSCHUTZ.EDU
A Novel Therapeutic Approach to Genitourinary Syndrome of Menopause
This project aims to address the genitourinary syndrome of menopause (GSM) in postmenopausal women, which includes symptoms like painful intercourse, incontinence, and increased vaginal and urinary tract infections. The proposed solution is a small molecule drug to be delivered locally via cream, tablet suppository, or vaginal ring that activates estrogen receptors to regenerate tissue locally. Unlike traditional estrogen-based therapies, this drug is designed to be rapidly inactivated, ensuring that it won't impose any systemic action. The team has conducted promising proof-of-principle studies in ovariectomized rats and plans to synthesize additional compounds, develop improved formulation strategies, and conduct efficacy and toxicity studies to determine appropriate dosing. If successful, this drug could benefit millions of postmenopausal women, including breast cancer survivors for whom estrogen-based therapies are contraindicated. The team brings together expertise in chemical synthesis, formulation, pharmacokinetics, and drug development, making them well-suited for this project. Collaborators: Steven Nordeen, PhD, David Orlicky, PhD and Thomas Anchordoquy, PhD
Learn more about Dr. Wempe